Srinagar Magazine

Myelodysplastic Syndrome Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies – Astex Pharma, Onconova, Celgene, Aprea Therapeutics, Celyad, and Others

 Breaking News
  • No posts were found

Myelodysplastic Syndrome Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies – Astex Pharma, Onconova, Celgene, Aprea Therapeutics, Celyad, and Others

July 28
02:15 2022
Myelodysplastic Syndrome Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies -  Astex Pharma, Onconova, Celgene, Aprea Therapeutics, Celyad, and Others
Delveinsight Business Research LLP
As per DelveInsight, the Myelodysplastic Syndrome Market dynamics are expected to transform in the coming years owing to the launch of emerging therapies, ongoing Research and Development (R&D) activities, and the active participation of the global pharma and biotech giants in the therapeutic segment.

DelveInsight’s “Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Myelodysplastic Syndrome Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Myelodysplastic Syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Myelodysplastic Syndrome: An Overview

Myelodysplastic syndrome (MDS) constitutes a group of clonal myeloid neoplasms characterized by anemia or other cytopenias due to ineffective hematopoiesis, abnormal blood and bone marrow cell morphology, as well as, the risk for clonal evolution and progression to acute myeloid leukemia (AML). 

Although the causative agents for Myelodysplastic Syndrome are not specific, however, a various range of factors such as genetic mutations, exposure to toxic heavy metals, harmful chemicals (such as tobacco, pesticides, and benzene) along with prior exposure to chemotherapy or radiation therapy may act as trigger points. Currently, the detected recurrent mutations involve nearly 30 genes, which are mainly classified into four functional groups. 

Myelodysplastic Syndrome Market Key Facts

  • According to population-based registry data (1993–2008) analysis in Japan, the incidence of MDS sharply increased with age, particularly in those over age 70 years. The incidence in 65–69 years was reported to be 3.1 cases/100,000 (men) and 1.1 cases/100,000 (women), compared to 85 years in which the rate was 17.7 and 8.9 cases/100,000, respectively.

  • According to DelveInsight’s analysis, males are affected more than females in the case of Myelodysplastic Syndrome (MDS).

  • In MDS-RS, a minimum of 15% of the early red blood cells must be ring sideroblast with a mutation in the SF3B1 gene. It can be divided into two categories (MDS-RS-SLD, and MDS-RS-MLD) and rarely turns into AML.

Myelodysplastic Syndrome Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Myelodysplastic Syndrome market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report details the Myelodysplastic Syndrome market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Myelodysplastic Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Myelodysplastic Syndrome Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myelodysplastic Syndrome market or expected to be launched during the study period. The analysis covers the Myelodysplastic Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Myelodysplastic Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-market

Myelodysplastic Syndrome Therapeutics Analysis

Some of the key companies in the Myelodysplastic Syndrome market include:

  • Astex Pharmaceuticals

  • Onconova Therapeutics

  • Celgene

  • Aprea Therapeutics

  • Celyad

And many others.

Myelodysplastic Syndrome Therapies covered in the report include:

  • Guadecitabine (SGI-110)

  • Rigosertib

  • APR-246

  • CYAD-02

  • CC-90009

And others.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –  https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Myelodysplastic Syndrome Competitive Intelligence Analysis

4. Myelodysplastic Syndrome Market Overview at a Glance

5. Myelodysplastic Syndrome Disease Background and Overview

6. Myelodysplastic Syndrome Patient Journey

7. Myelodysplastic Syndrome Epidemiology and Patient Population

8. Myelodysplastic Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Myelodysplastic Syndrome Unmet Needs

10. Key Endpoints of Myelodysplastic Syndrome Treatment

11. Myelodysplastic Syndrome Marketed Products

12. Myelodysplastic Syndrome Emerging Therapies

13. Myelodysplastic Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. Myelodysplastic Syndrome Market Outlook (7 major markets)

16. Myelodysplastic Syndrome Access and Reimbursement Overview

17. KOL Views on the Myelodysplastic Syndrome Market.

18. Myelodysplastic Syndrome Market Drivers

19. Myelodysplastic Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-market

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Other Healthcare Reports by DelveInsight

Physiotherapy Equipment Market

Physiotherapy Equipment Market” Research Report provides comprehensive insights into the historical and forecasted Physiotherapy Equipment Market size, share, trends, and growth estimation. It also covers the latest breakthroughs, collaboration, latest innovations, emerging devices, and key companies working in the global market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/malignant-mesothelioma-market

Related Articles